SCHEMBL4316174

SCHEMBL4316174

CN(CC1COCCO1)S(=O)(=O)Nc1cc2c(=O)c3cc(-c4cnn(C)c4)cnc3ccc2cn1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 20/20 0.84
▸ MST1R Q04912 2/20 0.84
▸ AURKA O14965 1/20 0.84
▸ JAK2 O60674 1/20 0.84
▸ ABL1 P00519 1/20 0.84
▸ NTRK1 P04629 1/20 0.84
▸ RET P07949 1/20 0.84
▸ CYP3A4 P08684 1/20 0.84
▸ PDGFRB P09619 1/20 0.84
▸ FGFR1 P11362 1/20 0.84
▸ CYP2C9 P11712 1/20 0.84
▸ NQO2 P16083 1/20 0.84
▸ FLT1 P17948 1/20 0.84
▸ FGFR2 P21802 1/20 0.84
▸ FGFR3 P22607 1/20 0.84
▸ FECH P22830 1/20 0.84
▸ FLT4 P35916 1/20 0.84
▸ KDR P35968 1/20 0.84
▸ FLT3 P36888 1/20 0.84
▸ MAPK9 P45984 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mk-2461 SCHEMBL2326614 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL2326906 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29394185 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29356324 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL93526 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29529144 0.92 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269865 0.91 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1270766 0.91 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1270764 0.91 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269863 0.91 MET (0.98) METMST1RAURKAJAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US claimed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 — — US disclosed
WO-2007050383-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131423-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET MET 3/4885MST1R 273/4885AURKA 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback